Firm hopes FDA will make therapy, revenue possible
This is the year a start-up generic drug firm from Cranberry could produce its first revenue, if it can battle its way out of the courts and win Food and Drug Administration approval for its inaugural product.
[more]
Read More >>
Label Issues Are Delaying Generic Drugs
They are still waiting.
[more]
Read More >>
Three Rivers Counter-Sues Schering Plough Corporation Over Ribavirin Patent Issue
Read More >>
By Pamela Gaynor, Post-Gazette Staff Writer
Correction/Clarification: (Published April 18, 2002) In our April 11 story about Three Rivers Pharmaceuticals, we said Hepatitis C is contracted through contact with unsterile needles. In reality, blood is the medium through which the disease is transmitted, and needles are only one source of contaminated blood.
Anyone in Pittsburgh who thinks about generic drug makers probably thinks automatically of Mylan Laboratories, not tiny Three Rivers Pharmaceuticals.
Mylan, of course, is a granddaddy in the industry, accustomed to doing combat with brand-name drug makers that don’t easily give up long-held rights to pharmaceutical compounds — even when their patents reach expiration.
Three Rivers, on the other hand, is a mere wannabe, just trying to break into the business. At this point, it has no sales, not even a pill that it’s permitted to sell.
[more]
Read More >>
Three Rivers Counter-Sues Schering Plough Corporation Over Ribavirin Patent Issue
November 26, 2001
Three Rivers Pharmaceuticals, LLC, a startup generic drug manufacturer, last week sued Schering Corporation in United States Federal District Court for the Western District of Pennsylvania. Three Rivers asserts that Schering has engaged in unfair competition under Pennsylvania law. [more]
Read More >>